Cargando…

Formulation of Folate-Modified Raltitrexed-Loaded Nanoparticles for Colorectal Cancer Theranostics

Multifunctional nanoparticles (NPs) that enable the imaging of drug delivery and facilitate cancer cell uptake are potentially powerful tools in tailoring oncologic treatments. Here we report the development of a layer-by-layer (LbL) formulation of folic acid (FA) and folate antimetabolites that hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosch, Justin G., DuRoss, Allison N., Landry, Madeleine R., Sun, Conroy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076500/
https://www.ncbi.nlm.nih.gov/pubmed/32033317
http://dx.doi.org/10.3390/pharmaceutics12020133
_version_ 1783507231358058496
author Rosch, Justin G.
DuRoss, Allison N.
Landry, Madeleine R.
Sun, Conroy
author_facet Rosch, Justin G.
DuRoss, Allison N.
Landry, Madeleine R.
Sun, Conroy
author_sort Rosch, Justin G.
collection PubMed
description Multifunctional nanoparticles (NPs) that enable the imaging of drug delivery and facilitate cancer cell uptake are potentially powerful tools in tailoring oncologic treatments. Here we report the development of a layer-by-layer (LbL) formulation of folic acid (FA) and folate antimetabolites that have been well-established for enhanced tumor uptake and as potent chemotherapeutics, respectively. To investigate the uptake of LbL coated NPs, we deposited raltitrexed (RTX) or combined RTX-FA on fluorescent polystyrene NPs. The performance of these NP formulations was evaluated with CT26 murine colorectal cancer (CRC) cells in vitro and in vivo to examine both uptake and cytotoxicity against CRC. Fluorescence microscopy and flow cytometry indicated an increased accumulation of the coated NP formulations versus bare NPs. Ex vivo near-infrared (NIR) fluorescence imaging of major organs suggested the majority of NPs accumulated in the liver, which is typical of a majority of NP formulations. Imaging of the CRC tumors alone showed a higher average fluorescence from NPs accumulated in animals treated with the coated NPs, with the majority of RTX NP-treated animals showing the consistently-highest mean tumoral accumulation. Overall, these results contribute to the development of LbL formulations in CRC theranostic applications.
format Online
Article
Text
id pubmed-7076500
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70765002020-03-20 Formulation of Folate-Modified Raltitrexed-Loaded Nanoparticles for Colorectal Cancer Theranostics Rosch, Justin G. DuRoss, Allison N. Landry, Madeleine R. Sun, Conroy Pharmaceutics Article Multifunctional nanoparticles (NPs) that enable the imaging of drug delivery and facilitate cancer cell uptake are potentially powerful tools in tailoring oncologic treatments. Here we report the development of a layer-by-layer (LbL) formulation of folic acid (FA) and folate antimetabolites that have been well-established for enhanced tumor uptake and as potent chemotherapeutics, respectively. To investigate the uptake of LbL coated NPs, we deposited raltitrexed (RTX) or combined RTX-FA on fluorescent polystyrene NPs. The performance of these NP formulations was evaluated with CT26 murine colorectal cancer (CRC) cells in vitro and in vivo to examine both uptake and cytotoxicity against CRC. Fluorescence microscopy and flow cytometry indicated an increased accumulation of the coated NP formulations versus bare NPs. Ex vivo near-infrared (NIR) fluorescence imaging of major organs suggested the majority of NPs accumulated in the liver, which is typical of a majority of NP formulations. Imaging of the CRC tumors alone showed a higher average fluorescence from NPs accumulated in animals treated with the coated NPs, with the majority of RTX NP-treated animals showing the consistently-highest mean tumoral accumulation. Overall, these results contribute to the development of LbL formulations in CRC theranostic applications. MDPI 2020-02-05 /pmc/articles/PMC7076500/ /pubmed/32033317 http://dx.doi.org/10.3390/pharmaceutics12020133 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rosch, Justin G.
DuRoss, Allison N.
Landry, Madeleine R.
Sun, Conroy
Formulation of Folate-Modified Raltitrexed-Loaded Nanoparticles for Colorectal Cancer Theranostics
title Formulation of Folate-Modified Raltitrexed-Loaded Nanoparticles for Colorectal Cancer Theranostics
title_full Formulation of Folate-Modified Raltitrexed-Loaded Nanoparticles for Colorectal Cancer Theranostics
title_fullStr Formulation of Folate-Modified Raltitrexed-Loaded Nanoparticles for Colorectal Cancer Theranostics
title_full_unstemmed Formulation of Folate-Modified Raltitrexed-Loaded Nanoparticles for Colorectal Cancer Theranostics
title_short Formulation of Folate-Modified Raltitrexed-Loaded Nanoparticles for Colorectal Cancer Theranostics
title_sort formulation of folate-modified raltitrexed-loaded nanoparticles for colorectal cancer theranostics
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076500/
https://www.ncbi.nlm.nih.gov/pubmed/32033317
http://dx.doi.org/10.3390/pharmaceutics12020133
work_keys_str_mv AT roschjusting formulationoffolatemodifiedraltitrexedloadednanoparticlesforcolorectalcancertheranostics
AT durossallisonn formulationoffolatemodifiedraltitrexedloadednanoparticlesforcolorectalcancertheranostics
AT landrymadeleiner formulationoffolatemodifiedraltitrexedloadednanoparticlesforcolorectalcancertheranostics
AT sunconroy formulationoffolatemodifiedraltitrexedloadednanoparticlesforcolorectalcancertheranostics